1. Home
  2. MMI vs RCUS Comparison

MMI vs RCUS Comparison

Compare MMI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMI
  • RCUS
  • Stock Information
  • Founded
  • MMI 1971
  • RCUS 2015
  • Country
  • MMI United States
  • RCUS United States
  • Employees
  • MMI N/A
  • RCUS N/A
  • Industry
  • MMI Real Estate
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MMI Finance
  • RCUS Health Care
  • Exchange
  • MMI Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • MMI 1.2B
  • RCUS 1.2B
  • IPO Year
  • MMI 2013
  • RCUS 2018
  • Fundamental
  • Price
  • MMI $27.95
  • RCUS $13.90
  • Analyst Decision
  • MMI Hold
  • RCUS Buy
  • Analyst Count
  • MMI 1
  • RCUS 7
  • Target Price
  • MMI N/A
  • RCUS $22.00
  • AVG Volume (30 Days)
  • MMI 123.3K
  • RCUS 937.9K
  • Earning Date
  • MMI 11-07-2025
  • RCUS 11-05-2025
  • Dividend Yield
  • MMI 1.77%
  • RCUS N/A
  • EPS Growth
  • MMI N/A
  • RCUS N/A
  • EPS
  • MMI N/A
  • RCUS N/A
  • Revenue
  • MMI $725,903,000.00
  • RCUS $262,000,000.00
  • Revenue This Year
  • MMI $9.50
  • RCUS N/A
  • Revenue Next Year
  • MMI $17.73
  • RCUS N/A
  • P/E Ratio
  • MMI N/A
  • RCUS N/A
  • Revenue Growth
  • MMI 17.89
  • RCUS 6.07
  • 52 Week Low
  • MMI $27.61
  • RCUS $6.50
  • 52 Week High
  • MMI $42.80
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • MMI 26.76
  • RCUS 68.53
  • Support Level
  • MMI $28.25
  • RCUS $12.89
  • Resistance Level
  • MMI $29.38
  • RCUS $16.12
  • Average True Range (ATR)
  • MMI 0.70
  • RCUS 0.73
  • MACD
  • MMI -0.29
  • RCUS 0.07
  • Stochastic Oscillator
  • MMI 6.22
  • RCUS 44.17

About MMI Marcus & Millichap Inc.

Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: